<unk>  can be co-prescribed with other psychiatric drugs, such as antidepressants, anxiolytics and antipsychotics, in which case it can interact with them. Most problematic interactions are generally additive or synergistic, such that, when drugs are combined, their effects intensify, which usually manifests as an increase in side effects, but can also be dangerous, depending on the drugs involved. While<unk>  is not a monoamine reuptake inhibitor, any irreversible MAOIs should still be discontinued at least 14 days before treatment.<unk>  can compete with other TCAs, beta blockers, antiarrhythmics (of class 1c) and other drugs for microsomal enzymes, which can lead to slower metabolism and higher plasma concentrations of these drugs. Co-administration of antipsychotics (e.g., haloperidol, risperidone) can increase the plasma concentration of<unk> . Barbiturates and anticonvulsants, on the other hand, can reduce the plasma concentration of<unk>  and thereby weaken its therapeutic effect.
Opipramol
Stiripentol
Fenproporex
Mitapivat
Florbetapir 
Avacopan
Vigabatrin
Piritramide